Nav: Home

Nonfunctional adrenal tumors significantly increase risk for diabetes

August 01, 2016

1. Patients with "nonfunctional" adrenal tumors at significantly higher risk for diabetes
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-0547
URL goes live when the embargo lifts

Patients with nonfunctional adrenal tumors have a significantly higher risk for diabetes compared to patients without adrenal tumors. These findings suggest that a classification of "nonfunctional" may not adequately describe the continuum of hormone secretion and metabolic risk associated with benign adrenal tumors. The study is published in Annals of Internal Medicine.

Adrenal tumors are typically benign and affect up to 10 percent of the population. While benign adrenal tumors are commonly thought to be nonfunctional, a substantial proportion may be functional in that they secrete detectable adrenocortical hormones. Known as subclinical hypercotisolism, the condition is associated with hypertension, insulin resistance, type 2 diabetes, hyperlipidemia, osteoporosis, and obesity. In recent studies, subclinical hypercotisolism was linked to an increased risk for cardiovascular events and death compared to nonfunctional adrenal tumors. Therefore, screening for hypercortisolism is recommended for all patients with adrenal tumors. However, emerging evidence suggests that nonfunctional adrenal tumors may be associated with cardiometabolic disease.

Researchers compared medical records for 166 patients with benign nonfunctional adrenal tumors to those of 740 patients with no adrenal tumor to look for development of cardiometabolic outcomes, such as hypertension, diabetes, or cardiovascular events. They found that patients with nonfunctional adrenal tumors were significantly more likely to develop diabetes than those without adrenal tumors. These findings suggest that nonfunctional adrenal tumors may warrant more clinical attention and should be considered an independent risk factor for diabetes.

Note: For an embargoed PDF, please contact Cara Graeff. To reach the lead author, Dr. Anand Vaidya, please contact Haley Bridger at hbridger@partners.org or 617-525-6383.




2. Trend report: No increase in overall prevalence of late stage chronic kidney disease over the past decade
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-0273
Editorial: http://www.annals.org/article.aspx?doi=10.7326/M16-1649
URL goes live when the embargo lifts

In a reversal of previous trends, no increase in the prevalence of stage 3 and 4 chronic kidney disease (CKD) has been seen in the U.S. population over the most recent decade. The findings are published in Annals of Internal Medicine.

CKD is recognized as an important risk factor for end-stage renal disease, acute kidney injury, cardiovascular disease, and premature death. As such, national health programs, such as the U.S. Department of Health and Human Services' Healthy People 2020 initiative, have set a target of a 10 percent proportional reduction in CKD prevalence in the U.S. population. While peer-reviewed publications have mostly reported that the overall prevalence of CKD in the U.S. population had been increasing by as much as 5 percent per year, it has been noted that the incidence rate of end-stage renal disease, which is almost always preceded by CKD, have been decreasing since the early 2000s. However, an important limitation in the peer-reviewed literature is that CKD prevalence in more recent years has not been analyzed.

Researchers analyzed data from the national Health and Nutrition Examination Survey (NHANES) to estimate the trends in CKD prevalence overall and in subgroups of the population, with particular attention given to more recent years. They found that stage 3 and 4 CKD has not increased appreciably in the U.S. population overall during the most recent decade. The lack of increase was noted in most subgroups examined when data were stratified by age, sex, race/ethnicity, and diabetes status, except for among non-Hispanic black persons. The authors express concern over these findings and suggest further research to better understand potentially important differences in patterns by racial/ethnic subgroups. The research could help to inform strategies for improving CKD prevalence trends for all population groups.

Note: For an embargoed PDF, please contact Cara Graeff. The lead author, Dr. Chi-yuan Hsu, can be reached through Katherine "Leigh" Beeson at Katherine.Beeson@ucsf.edu.




3. Patients should weigh benefits and risks when medication to reduce breast cancer risk is recommended
Annals of Internal Medicine and Beth Israel Deaconess Medical Center go "Beyond the Guidelines" to discuss pharmacological interventions to reduce breast cancer risk
Free content: http://www.annals.org/article.aspx?doi=10.7326/M16-0940
URL goes live when the embargo lifts

Should a 51 year-old woman with a strong family history of breast cancer be offered medication to reduce her own breast cancer risk? An oncologist and an internist debate the topic in a multicomponent educational article being published in Annals of Internal Medicine.

Clinical guidelines from the U.S. Preventive Services Task Force recommend that physicians discuss treatment with selective estrogen receptor modulators (tamoxifen, raloxifene) with their postmenopausal patients that have an increased 5-year risk for breast cancer, as the benefits of treatment may outweigh the potential harms. Similarly, the American Society of Clinical Oncology recommends that women aged 35 years or older at increased risk for breast cancer discuss the use of preventative medications, including the aromatase inhibitor exemestane, which is not approved by the FDA for this purpose, with their primary care providers. In this Beyond the Guidelines article, an oncologist and a primary care physician debate whether or not to prescribe pharmacotherapy for a premenopausal patient who does not fit exactly within guideline parameters. Both physicians agree that shared decision making is essential and must include informing the patient of the specific benefits and risks associated with treatment.

All Beyond the Guidelines papers are based on the Department of Medicine Grand Rounds at Beth Israel Deaconess Medical Center in Boston. Each session focuses on care of a patient who "falls between the cracks" in available evidence and for whom the optimal clinical management is unclear. Such situations include those in which a guideline finds evidence insufficient to make a recommendation, a patient does not fit criteria mapped out in recommendations, or different organizations provide conflicting recommendations. Debates are presented in a question and answer format, and include video interviews with the patient and physicians. A list of topics is available at http://www.annals.org/grandrounds.

Note: For an embargoed PDF, please contact Cara Graeff. To interview the lead author, please contact Lizzie Williamson at erwillia@bidmc.harvard.edu or 617-632-8217.




Also in this issue:

Bioequivalence of Biosimilar Tumor Necrosis Factor-_ Inhibitors Compared With Their Reference Biologics: A Systematic Review and Meta-analysis
Francine Chingcuanco, MHS; Jodi Segal, MD, MPH; Seoyoung C. Kim, MD, ScD, MSCE; and G. Caleb Alexander, MD
Review
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-0428

The Biosimilarity Concept: Toward an Integrated Framework for Evidence Assessment
Issam Zineh, PharmD, MPH; Leah A. Christl, PhD
Editorial
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-1559

Annals Graphic Medicine - I'd Want a Natural Death
Nathan Gray, MD
Graphic Medicine
Free content: http://www.annals.org/article.aspx?doi=10.7326/G16-0002

Visceral Vistas: Basil Hirschowitz and the Birth of Fiberoptic Endoscopy
Ian S. Campbell, MD; Joel D. Howell, MD, PhD; and H. Hughes Evans, MD, PhD
History of Medicine
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-0025
-end-


American College of Physicians

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.